The estimated Net Worth of Deborah Turner Kochevar is at least $5.96 million dollars as of 6 August 2021. Deborah Kochevar owns over 3,526 units of Charles River Laboratories International stock worth over $1,180,125 and over the last 16 years he sold CRL stock worth over $4,460,608. In addition, he makes $314,856 as Independent Director at Charles River Laboratories International.
Sign up
Deborah Kochevar CRL stock SEC Form 4 insiders trading
Deborah has made over 14 trades of the Charles River Laboratories International stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 3,526 units of CRL stock worth $1,433,072 on 6 August 2021.
The largest trade he's ever made was exercising 29,650 units of Charles River Laboratories International stock on 9 May 2011 worth over $926,563. On average, Deborah trades about 2,501 units every 98 days since 2008. As of 6 August 2021 he still owns at least 6,096 units of Charles River Laboratories International stock.
You can see the complete history of Deborah Kochevar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Deborah Kochevar biography
Dr. Deborah Turner Kochevar, D.V.M., Ph.D. is an Independent Director of Charles River Laboratories International Inc. Senior Fellow, The Fletcher School of Law and Diplomacy, with a focus on Global One Health and health diplomacy, and Dean Emerita of Cummings School of Veterinary Medicine at Tufts University. From 2018 until 2019, Dr. Kochevar served as Provost and Senior Vice President ad interim and, from 2006 until 2018, as Dean of Cummings School of Veterinary Medicine at Tufts University. Previously, Dr. Kochevar was a long-time faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a past-president of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar serves as a director at Elanco Inc. Dr. Kochevar has been a director since October 2008. Senior Fellow, The Fletcher School of Law and Diplomacy, with a focus on Global One Health and health diplomacy, and Dean Emerita of Cummings School of Veterinary Medicine at Tufts University. From 2018 until 2019, Dr. Kochevar served as Provost and Senior Vice President ad interim and, from 2006 until 2018, as Dean of Cummings School of Veterinary Medicine at Tufts University. Previously, Dr. Kochevar was a long-time faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a past-president of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology.
What is the salary of Deborah Kochevar?
As the Independent Director of Charles River Laboratories International, the total compensation of Deborah Kochevar at Charles River Laboratories International is $314,856. There are 16 executives at Charles River Laboratories International getting paid more, with James Foster having the highest compensation of $17,722,100.
How old is Deborah Kochevar?
Deborah Kochevar is 63, he's been the Independent Director of Charles River Laboratories International since 2008. There are 9 older and 12 younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International Inc. is Stephen Chubb, 76, who is the Independent Director.
What's Deborah Kochevar's mailing address?
Deborah's mailing address filed with the SEC is C/O CHARLES RIVER LABORATORIES, 251 BALLARDVALE STREET, WILMINGTON, MA, 01887.
Insiders trading at Charles River Laboratories International
Over the last 22 years, insiders at Charles River Laboratories International have traded over $220,588,205 worth of Charles River Laboratories International stock and bought 18,392 units worth $3,841,397 . The most active insiders traders include James C Foster, Richard F Wallman et David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of $2,223,188. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth $354,861.
What does Charles River Laboratories International do?
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
What does Charles River Laboratories International's logo look like?
Complete history of Deborah Kochevar stock trades at Charles River Laboratories International et Elanco Animal Health Inc
Charles River Laboratories International executives and stock owners
Charles River Laboratories International executives and other stock owners filed with the SEC include:
-
James Foster,
Chairman of the Board, President, Chief Executive Officer -
David Smith,
Chief Financial Officer, Corporate Executive Vice President -
James C. Foster,
Chairman, CEO & Pres -
Joseph LaPlume,
Corporate Executive Vice President, Corporate Development and Strategy -
Birgit Girshick,
Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian -
William Barbo,
Corporate Executive Vice President and Chief Commercial Officer -
David Ross Smith,
Corp. Exec. VP & CFO -
William D. Barbo,
Chief Commercial Officer & Corp. Exec. VP -
Joseph W. LaPlume,
Corp. Exec. VP of Corp. Devel. & Strategy -
Birgit Girshick,
Corp. Exec. VP & COO -
George Milne,
Lead Independent Director -
George Massaro,
Independent Director -
Robert Bertolini,
Independent Director -
Richard Reese,
Independent Director -
Richard Wallman,
Independent Director -
Martin Mackay,
Independent Director -
Deborah Kochevar,
Independent Director -
Jean-Paul Mangeolle,
Independent Director -
Stephen Chubb,
Independent Director -
Virginia Wilson,
Independent Director -
Nancy Andrews,
Independent Director -
George Llado,
Director -
Matthew L. Daniel,
Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Todd Spencer,
Corp. VP of Investor Relations -
Mark Mintz,
Corp. Sr. VP & Chief Information Officer -
Prof. Julie Frearson Ph.D.,
Corp. Sr. VP & Chief Scientific Officer -
Michael Gunnar Knell,
Corp. Sr. VP & Chief Accounting Officer -
John J Crowley,
SVP, Chief Accounting Officer -
Davide Molho,
Corporate Executive VP -
Michael Gunnar Knell,
CSVP&Chief Accounting Officer -
Craig B. Thompson,
Director -
John W Kuo,
CEVP General Counsel & CCO -
Victoria L Creamer,
EVP & Chief People Officer -
David P Johst,
Corporate Executive VP -
Jorg Geller,
OFFICERS -
Nancy Gillett,
Vice President -
Thomas F Ackerman,
Sr. Vp and CFO -
Samuel O Md Thier,
Director -
William Waltrip,
Director -
Nancy T Chang,
Director -
Christopher Berthoux,
OFFICERS -
Douglas E Rogers,
Director -
Real H Renaud,
Executive Vice President -
Brian Bathgate,
Corporate Vice President -
Joanne P Acford,
Corp. Sr VP, GC and Corp. Sec -
David J Elliott,
Officer -
Linda Mc Goldrick,
Director -
Stephanie B Wells,
Senior Vice President -
Cheri L Walker,
Corporate Senior VP -
Nicholas Ventresca,
Senior Vice President -
Michael F Ankcorn,
Corporate Sr. Vice President -
Walter S Nimmo,
Director -
S Louise Mccrary,
Director -
John C Ho,
Senior Vice President -
Alastair Stuart Mcewan,
Corporate Vice President -
John Urquhart,
Director -
Dennis R Shaughnessy,
Sr. VP Corporate Development -
Robert Cawthorn,
Director -
Flavia Pease,
Corporate Executive VP & CFO -
Shannon M Parisotto,
CEVP, Disc & Safety Assessment -
Reshema Kemps Polanco,
Director